-
公开(公告)号：US20220023172A1
公开(公告)日：2022-01-27
申请号：US17297349
申请日：2019-11-27
Applicant: Kristina TRUJILLO , Katie UILK , David L. VANDER JAGT , Lorraine M. DECK , STC.UNM , K&K BIOTECH
Inventor： Kristina Trujillo , Katie Uilk , David L. Vander Jagt , Lorraine M. Deck
Abstract: The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFKB and as agonists (activators) of Nrf2. In particular, these compounds show dual activity and it has been discovered that these compounds are particularly useful in the treatment of certain cosmetic applications and in rejuvenating and beautifying skin and other keratinous tissue of a subject in need. Cosmetic compositions and methods of using said compositions in combination with other components are disclosed herein.
-
公开(公告)号：US20160346334A1
公开(公告)日：2016-12-01
申请号：US15116579
申请日：2015-02-05
Applicant: STC.UNM
Inventor： Kristina Trujillo
CPC classification number: A61K35/55 , A61K9/0019 , A61K31/138 , A61K31/337 , A61K31/513 , A61K35/12 , A61K38/00 , A61K39/00 , A61K45/06 , A61K2300/00
Abstract: In one embodiment, the invention provides substantially purified exosomes which induce apoptosis in breast cancer cells and which are derived from a cultured medium of histologically normal breast tissue cells that are obtained from tumor-adjacent normal breast tissue. Related methods of treating breast cancer and pharmaceutical formulations are also provided.
Abstract translation: 在一个实施方案中，本发明提供了在乳腺癌细胞中诱导细胞凋亡的基本上纯化的外来体，其衍生自从肿瘤相邻的正常乳腺组织获得的组织学上正常的乳腺组织细胞的培养基。 还提供了治疗乳腺癌和药物制剂的相关方法。
-
公开(公告)号：US10548950B2
公开(公告)日：2020-02-04
申请号：US15528348
申请日：2015-11-18
Applicant: STC.UNM
Inventor： Kristina Trujillo , Nicholas Patrick Gannon , Roger Alan Vaughan
IPC: A61K39/00 , A61K38/22 , A61K45/06 , A61K31/704 , A61K31/337
Abstract: In one embodiment, the invention provides methods of treating or preventing cancer, in particular aspects breast and/or prostate cancer, by administering to a subject in need thereof a therapeutically-effective amount of irisin and, optionally, one or more adjuvant therapies (e.g. synergistic co-administration of an additional anti-cancer agent or chemotherapy). Related pharmaceutical compositions, assays and kits are also provided.
-
公开(公告)号：US20170312339A1
公开(公告)日：2017-11-02
申请号：US15528348
申请日：2015-11-18
Applicant: STC.UNM
Inventor： Kristina Trujillo , Nicholas Patrick Gannon , Roger Alan Vaughan
IPC: A61K38/22 , A61K31/337 , A61K31/704 , A61K45/06
CPC classification number: A61K38/22 , A61K31/155 , A61K31/337 , A61K31/704 , A61K38/177 , A61K45/06 , G01N33/74 , G01N2800/7028 , A61K2300/00
Abstract: In one embodiment, the invention provides methods of treating or preventing cancer, in particular aspects breast and/or prostate cancer, by administering to a subject in need thereof a therapeutically-effective amount of irisin and, optionally, one or more adjuvant therapies (e.g. synergistic co-administration of an additional anti-cancer agent or chemotherapy). Related pharmaceutical compositions, assays and kits are also provided.
-
-
-
Search Results
4
records
(took 0.014 seconds)
